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Abstract Current asthma management guidelines state that where a patient is receiving a low to moderate dose of 
inhaled corticosteroids and is still experiencing symptoms the dose ofcorticosteroid should be increased and, if neces- 
sary, a long-acting bronchodilator should be added. Many studies have now shown thatthe addition ofa/~2-agonist with 
long-acting properties is more effective at controlling asthma symptoms than increasing the dose ofcorticosteroid alone. 
The Formoterol and Corticosteroid EstablishingTherapy (FACET) study was a 12_-month study comparing exacerbation 
rates in patients treated with budesonide (100 itg or 400 ILg) twice daily alone vs. treatment with budesonide (100 #g or 
400 #g) twice daily plus formoterol 9 #g twice daily (delivered dose) (I). The addition of formoterol reduced the rates of 
mild and severe exacerbations compared with budesonide alone, with the lowest rates seen in patients receiving high- 
dose budesonide and formoterol. There was no difference in the profile of exacerbations in any groups, indicating for- 
moterol does not masl< any signs of inflammation. The addition offormoterol to budesonide was also shown to result in 
improved lung function (as measured by peal<expiratory flow rate and forced expiratory volume in I second), night-time 
awakenings and the use of as-needed medication when compared with an increase in the dose of budesonide. In all cases, 
increasing the dose of budesonide and addition offormoterol resulted in the most improvement and a significant increase 
in quality of life, measured by Asthma Quality of Life Questionnaire (AQLQ), was noted. In conclusion, the addition of 
formoterol to established treatment with inhaled corticosteroids provides superior asthma control compared with an 
increase in the dose ofcorticosteroid alone. 
© 2001 Harcourt Publishers Ltd 
doi:10.1053/rmed,2001,1140 
INTRODUCTION 
Over the past 100 years, the management of asthma has 
changed considerably. In the early part of the twentieth 
century asthma was recognized as a chronic disorder, but 
treatment was aimed at treating exacerbations, with little 
attention to the ongoing, day-to-day complications. With 
the introduction of first adrenaline and then oral corticos- 
teroids, both of which were derived from adrenal extract, 
treatment was aimed more at preventing these exacerba- 
tions. Great strides forward were made with the introduc- 
tion of inhaled therapy, both with short-acting/~2-agonists 
and, more recently; corticosteroids, in treating symptoms 
and providing maintenance therapy. Over time goals have 
changed, and we are now looking towards achievement of 
normal lung function for patients, rather than just prevent- 
ing symptoms and exacerbations. 
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Newer agents are becoming available and it is the use 
of these agents in combination with existing drugs that 
may help to achieve this goal. Such agents include salme- 
terol, a long-acting/~2-agonist, and formoterol, a/~2-ago- 
nist that has not only a long duration, but also a fast 
onset of action (2).These drugs have a potential applica- 
tion in maintenance therapy and, in the case of formoter- 
ol, also in as-needed therapy. Traditionally, if a patient 
was poorly controlled on a low to moderate dose of cor- 
ticosteroid, increasing the dose was the accepted treat- 
ment strategy. However, recent evidence suggests that 
adding a/~2-agonist with a long duration of effect to cur- 
rent therapy produces a greater improvement in asthma 
control compared with increasing the dose of corticos- 
teroid alone-patients have been shown to experience 
fewer symptoms, have improved lung function and re- 
quire less as-needed medication. Also, the rate of both 
mild and severe exacerbations has been shown to de- 
crease using this treatment strategy. 
For a time there was some debate about whether it 
was appropriate to use/}2-agonists regularly as mainte- 
nance therapy (3). Several studies have suggested an in- 
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crease in mortality and morbidity associated with regu- 
lar use of inhaled fl2-agonist bronchodilators, particu- 
larly fenoterol (4-6). Larger studies have since shown 
that maintenance therapy with fiz-agonists is not asso- 
ciated with increased risks compared with as-needed 
use. In theTRUSTstudy (The Regular Use of Salbutamol 
Trial), there was no evidence that regular use of inhaled 
salbutamol increased the exacerbation rate of asthma 
when compared with as-needed use (7). 
The aim of this paper is to review the position of fi2- 
agonists with long-acting properties and the place they 
have in combination therapy with inhaled corticosteroids. 
THE ADDIT ION OF LONG-ACTING fiz" 
AGONISTS TO INHALED STEROIDS 
The first study to suggest that the addition of long-acting 
fi2-agonists to inhaled corticosteroids would provide 
better asthma control was performed by Greening eta/. 
(8). The guidelines for asthma management at this time 
stated that in patients poorly controlled on a low dose 
of inhaled corticosteroid, the first step should be an in- 
crease in the dose. In this study, patients receiving in- 
haled beclomethasone dipropionate (BDP) 200 #g twice 
daily, who were still experiencing symptoms, were ran- 
domized to receive either salmeterol 50#g plus BDP 
200 #g twice daily or a higher dose of BDP, 500 #g twice 
daily, for 6 months. An improvement in lung function, 
measured by mean morning peak expiratory flow (PEF), 
was noted in both groups, but the difference was signifi- 
cantly greater in the salmeterol group at all time 
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Figure I. Effect on mean morning PEF rate of adding salme- 
terol to beclomethasone 200 tzg twice daily compared with in- 
creasing beclomethasone dose to 500¢zg twice daily (8). 
Changes from baseline (-+SE) in mean morning and evening 
PEF rate during 6 months' study treatment.  *P<O,05; 
**P < 001 ; ***P < 0001. (Reproduced with permission from The 
Lc~ncet.) 
points (P < 0.05) (Fig. I).When considering the use of as- 
needed relief medication and asthma symptoms (day- 
and night-time), the results in the salmeterol group were 
also significantly improved compared with increasing the 
dose of BDP alone. 
Similar results have been seen in a study by Woolcock 
eta/. (9) who randomized moderate and severe asthmatic 
patients, poorly controlled on BDP 500#g twice daily to 
receive either salmetero150 #g or 100 #g twice daily with 
their current dose of BDP or an increase in BDP to 
1000 #g twice daily. Even though these patients were in- 
itially receiving a higher dose of inhaled corticosteroids 
than taken in the Greening study, the addition of either 
dose of salmeterol produced a significant improvement 
in lung function compared with increasing the dose of 
BDP. Both salmeterol groups also had a significantly in- 
creased percentage of symptom-free days and nights and 
reduced use of as-needed relief medication compared 
with BDP. Interestingly, there was no difference between 
the two salmeterol groups and exacerbation rates did 
not differ between all three groups. A meta-analysis of 
nine studies has confirmed that addition of salmeterol 
to a low dose of inhaled corticosteroids gives better 
asthma control, in terms of reduced symptoms, im- 
proved lung function and reduced as-needed fi2-agonist 
use, than doubling the dose of inhaled corticosteroids 
00). 
A landmark trial in this area is the FACET trial, which 
compared the effects of adding formoterol to budeso- 
nide with budesonide only over a longer period than pre- 
viously studied, a total of 12 months (I). This study 
provided further evidence demonstrating that f l2-ago- 
nists with a long-acting profile do not have a detrimental 
effect on the long-term control of asthma. For the first 
time, frequency of exacerbations was chosen as the pri- 
mary outcome in a trial of this type, defined as either: I] 
severe, i.e. a requirement for oral glucocorticoids as 
judged by the investigator or following a decrease in the 
peak flow to more than 30% below the baseline value on 
2 consecutive days; or 2] mild, i.e. 2 consecutive days 
when morning peak flow decreased more than 20% be- 
low baseline, the use of more than three additional inha- 
lations of terbutaline in a 24h period or night-time 
awakening due to asthma. As exacerbation rates give a 
clear indication of disease advancement, this study pro- 
vides invaluable data about the underlying inflammatory 
disease. Other endpoints studied were lung function, 
measured by forced expiratory volume in I second 
(FEV 0 and PEF, asthma symptoms, night-time awaken- 
ings, and the requirement for as-needed fi2-agonist use. 
Patients with asthma taking a mean daily dose of bude- 
sonide 800#g were randomly assigned to one of four 
treatments delivered by means of a dry-powder inhaler 
(Turbuhaler"R): I] budesonide 100#g twice daily plus pla- 
cebo; 2] budesonide 100#g twice daily plus formoterol 
9#g twice daily, delivered dose; 3] budesonide 400#g 
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twice daily plus placebo; or 4] budesonide 400#g twice 
daily plus formoterol 9#g twice daily. During a 4-week, 
run-in period, patients were treated with a high dose of 
inhaled corticosteroid (budesonide 800 #g twice daily) to 
ensure they were stable and active treatment was then 
given for a 12-month period. Terbutaline was permitted 
as needed for relief of symptoms. 
When compared with budesonide 200 #g daily and pla- 
cebo, rates of severe and mild exacerbation were re- 
duced in all other groups, with the lowest rates seen in 
patients who received the higher dose of budesonide plus 
formoterol (Figs 2 and 3). Patients in this group had a re- 
duction in severe exacerbations of 63% (P < 0.001) and in 
mild exacerbations of 62% (P < 0.001). Although the de- 
crease in the rate of severe exacerbations was not unex- 
pected following previous research, the decrease in the 
rates of mild exacerbations observed had not been an- 
ticipated. 
It had been suggested that use of formoterol might 
mask any underlying inflammatory process, preventing 
symptoms and therefore disguising the build up to an 
acute attack. This would result in exacerbations with a 
more rapid onset and greater severity. Interestingly, 
further analysis from FACET showed the time course, 
severity and duration of exacerbations to be similar in 
each study group (11). 
During the run-in period FEV~ increased in all groups 
and increased further with the addition of formoterol 
(Fig. 4). The greatest increases were again observed in 
the group receiving budesonide 800#g and formoterol 
18#g daily, however, the addition of formoterol to low- 
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Figure 2. Rate of mild exacerbations during 12-months' treat- 
ment with formoterol and budesonide in the FACETstudy (I). In- 
creasing the dose of budesonide (A vs. C): P<0,001; adding 
formoterol, irrespective of budesonide dose (A+C vs. B+D): 
P<0.001, 
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Figure 3. Rate of severe exacerbations during O-months' 
treatment with formoterol and budesonide in the FACETstud 7 
(I). Increasing the dose of budesonide (A vs.C): P<0,001 : adding 
formoterol, irrespective of budesonide dose (A+C vs, B+D): 
P=0.01. 
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Figure 4. FEVI during the FACETstudy (I). FEV, is shown as a 
mean percentage ofthe predicted value during the run-in period 
and the treatment period.The bars indicate 2 SE. (Reproduced 
with permission from N Engl J led,) 
dose budesonide treatment had a greater effect than in- 
creasing the dose of budesonide alone. These results 
were maintained throughout the 12-month period of 
the study. Morning peak flow also increased on the addi- 
tion of formoterol. This response was greatest over the 
first 2 days of treatment and then decreased slightly, sug- 
gesting a small degree of tolerance had developed. After 
this time point, the peak flow remained stable for the 
rest of the 12-month period, and was significantly higher 
than either of the budesonide-only groups.The tolerance 
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produced was felt to have little or no clinical significance. 
The requirement for as-needed medication, symptom 
scores and the number of days with symptoms were all 
significantly lowered following the addition of formoter- 
ol compared with budesonide alone. 
The authors concluded that the addition of formoterol 
to budesonide resulted in superior asthma control com- 
pared with budesonide only over a long-term period.The 
greatest improvements were observed where the dose 
of budesonide was also increased. All treatments were 
well tolerated and no safety issues were identified. 
As quality of life is an important outcome indicator for 
patients, the Asthma Quality of Life Questionnaire 
(AQLQ) was completed in 470 patients who completed 
the FACET study and analysed separately (12). An in- 
crease in AQLQ after the initial improvement during 
the run-in phase was observed in patients treated with 
budesonide 400 #g plus formoterol 9/~g twice daily. This 
improvement was sustained throughout the 12-month 
study. However, the correlation between changes in 
AQLQ and the results observed with respect to asthma 
control were weak. 
Similar results as those seen in the FACET study 
have also been seen in a study in mild asthmatic patients. 
The addition of formoterol 4.5 #g twice daily to budeso- 
nide 100#g twice daily resulted in fewer severe exacer- 
bations and poorly controlled days compared 
with increasing the dose of budesonide to 2001~g twice 
daily (13). 
substantially mediate the anti-inflammatory actions of 
corticosteroids, observed both in vitro (16) and in viva (17). 
In these cost-conscious times it is important that 
any treatment is not only efficacious, but also cost-effec- 
tive. A group of independent physicians has estimated 
the average healthcare resources and productivity 
losses following exacerbations in FACET-like patients, 
and this information was evaluated against the clinical 
data from the FACET study (18). The conclusions were 
that, for a marginal net cost increase, considerable 
improvements for all outcome measurements were 
observed. 
What, then, are the implications for patients? Patients 
with mild to moderate asthma, experiencing mild 
exacerbations, frequent night-time awakenings, limited 
daytime activity and high use of as-needed medication 
would generally benefit from the addition of a fi2-agonist 
with long-acting properties. For those patients 
with more severe symptoms, i.e. frequent and severe 
asthma exacerbations, often requiring hospitalization 
or oral corticosteroid therapy, an increase in the dose 
of their inhaled corticosteroid plus a fl2-agonist with 
a long duration of effect is likely to improve their 
condition. Although the effect of adding formoterol to 
all patient subgroups needs to be researched further, 
it appears that this treatment strategy provides a cost- 
effective treatment with rapid control of symptoms 
and is both well tolerated and effective in the long 
term. 
CONCLUSIONS 
The evidence presented indicates that patients with 
poorly controlled asthma will benefit from the addition 
of a fiz-agonist with long-acting properties to their es- 
tablished inhaled corticosteroid treatment. Increases in 
lung function and improvement in symptom control have 
been observed and, very importantly, a reduction in 
both mild and severe exacerbations has been shown with 
formoterol. 
The mechanism for this effect is not understood. A 
possible explanation is that the dose-response curve for 
corticosteroids is relatively flat and, therefore, most of 
the anti-inflammatory effect can be obtained from lower 
doses of the drug (14). Thus, increasing the corticoster- 
aid dose would have little effect compared with adding a 
fi2-agonist with long-acting properties. 
Another possible reason for the decrease in exacerba- 
tion rate observed in the FACETstudy is the effect of for- 
moterol in stabilizing mast cells, which may result in 
additional protective effects against specific stimuli (15). 
It also appears that fi2-agonists with a long-acting profile 
may potentiate the effects achieved with corticosteroid 
alone. Research has shown that fi2-agonists are potent ac- 
tivators of gtucocorticoid receptors and this activity may 
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